I would assume it's also possible that DAC51 is not as specific in targeting FTO as Zantrene. So DAC51 may be inhibiting FTO but simultaneously doing something else which reduces the negative impact of FTO inhibition on the cancer cells.
- Forums
- ASX - By Stock
- Ann: Compelling Zantrene Preclinical Kidney Cancer Data
I would assume it's also possible that DAC51 is not as specific...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
-0.090(5.06%) |
Mkt cap ! $288.0M |
Open | High | Low | Value | Volume |
$1.78 | $1.78 | $1.63 | $449.0K | 263.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2300 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 8176 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2300 | 1.665 |
1 | 5180 | 1.650 |
1 | 500 | 1.635 |
5 | 19098 | 1.630 |
2 | 4461 | 1.625 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 8176 | 1 |
1.720 | 1160 | 1 |
1.735 | 3313 | 1 |
1.750 | 6000 | 1 |
1.790 | 1000 | 1 |
Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |